-
Retina (Philadelphia, Pa.) 04/2013; · 2.93 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: AIM: To evaluate the effects and stability of AcrySof toric intraocular lens (IOL) implantation in patients who had combined microincision vitrectomy surgery (MIVS) and phacoemulsification for vitreoretinal diseases and cataract with corneal astigmatism. METHODS: A retrospective comparative study with 20 patients (20 eyes) who had combined 23-gauge MIVS and phacoemulsification with regular corneal astigmatism (>1.00 dioptres) was done. 10 eyes had toric IOL and 10 eyes had non-toric IOL implantation. The main outcome measures were uncorrected visual acuity (UCVA), refractive cylinder and toric IOL axis rotation at postoperative months 1, 6, 12, 18 and 24. RESULTS: The mean UCVA of toric IOL was better than non-toric IOL at each postoperative period (p=0.019, 0.001, 0.007, 0.004 and 0.001, respectively). The mean absolute residual refractive cylinder of toric IOL was less than non-toric IOL at each postoperative period (p=0.001, <0.001, <0.001, <0.001 and <0.001, respectively). At month 24, the mean toric IOL axis rotation was 3.3±2.1°, which was within 5° in 80% and within 10° in 100%. CONCLUSIONS: Toric IOL implantation could be an effective method of correcting corneal astigmatism in patients who have vitreoretinal diseases and cataract. The toric IOL showed good rotational stability, even in vitrectomised eyes for 24 months.
The British journal of ophthalmology 02/2013; · 2.92 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: A 32-year-old male who had infective endocarditis complained of photophobia and blurred vision in both eyes. Biomicroscopic examination and fundus examination revealed anterior chamber reaction, vitritis, optic disc swelling, and Roth spots. He was diagnosed with bilateral nongranulomatous uveitis and treated with topical steroid eye drops and posterior sub-Tenon injection of triamcinolone. His visual symptoms were resolved within 1 week, and inflammation resolved within 4 weeks after treatment.
Korean Journal of Ophthalmology 02/2013; 27(1):58-60.
-
[show abstract]
[hide abstract]
ABSTRACT: We report the case of a patient with acute bilateral transient myopia, secondary angle-closure glaucoma, and choroidal detachment associated with oral administration of methazolamide.
A 51-year-old man developed bilateral transient myopia and secondary angle-closure glaucoma with choroidal detachment after oral administration of methazolamide. Both eyes presented a shallow anterior chamber and elevated intraocular pressure. Ultrasound biomicroscopy revealed annular ciliochoroidal effusion and diffuse thickening of the ciliary body. Angiography showed many scattered islands of hypofluorescence in both eyes.
Methazolamide was stopped and prednisolone given orally. Eight days after treatment initiation, clinical symptoms and signs had resolved. The abnormal findings on ultrasound biomicroscopy and angiography disappeared by 2 months.
Methazolamide can induce bilateral transient myopia, angle-closure glaucoma, and choroidal detachment. Prompt identification of the causative medications and subsequent discontinuation can induce rapid resolution of angle closure.
Japanese Journal of Ophthalmology 07/2012; 56(5):515-7. · 0.92 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The aim of this study was to investigate whether polymorphisms in the vascular endothelial growth factor A gene (VEGF-A) are associated with polypoidal choroidal vasculopathy (PCV) in a Korean population and whether they are associated with PCV phenotypes.
This was a case-control study comprising 111 patients with PCV and 123 control participants. The PCV and control groups were genotyped for five polymorphisms in VEGF-A. Clinical characteristics were evaluated, including best-corrected visual acuity, fundus findings, and angiography findings at the first visit. Main outcome measures were the genotypes of variants and association with phenotypes.
Only rs833069 in VEGF-A generated significant allelic associations with PCV (P = 2.24 × 10(-5)). As compared with the AA group, the GG genotype group in rs833069 had a 6.25-fold increased risk of PCV [P = 7.45 × 10(-5), 95% confidence interval (CI) 2.52-15.46] and the AG group had a 1.82-fold increased risk (P = 0.029, 95% CI 1.03-3.24). The haplotype CCGC in VEGF-A showed an association with PCV (P = 2.90 × 10(-5)). However, the phenotypic characteristics of PCV did not show an association with the rs833069 genotypes.
The rs833069 polymorphism in VEGF-A was significantly associated with the risk of PCV in a Korean population.
Japanese Journal of Ophthalmology 03/2012; 56(2):145-51. · 0.92 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: To investigate whether ARMS2 (rs10490924)/HTRA1 (rs11200638) variants are associated with polypoidal choroidal vasculopathy (PCV) in a Korean population and with various PCV phenotypes.
A case-control study comprised of 103 patients with PCV and 112 control subjects. The PCV and control groups were genotyped for ARMS2 (rs10490924) and HTRA1 (rs11200638) polymorphisms. Clinical characteristics were evaluated, including best-corrected visual acuity (BCVA), fundus findings, and angiographic findings, at first visit.
Two single nucleotide polymorphisms generated highly significant allelic associations with PCV. The frequency of vitreous hemorrhage (VH) was different among the genotypes with respect to both rs10490924 and rs11200638. The frequency of the T allele of rs10490924 was higher in PCV patients with VH than in PCV patients without VH. The frequency of the A allele of rs11200638 was higher in PCV patients with VH than in PCV patients without VH. In rs10490924, the mean BCVA of the GG genotype group was better than that of the TT and TG genotype groups. In rs11200638, the mean BCVA of the GG genotype group was better than that of the AA and AG genotype groups.
The ARMS2 (rs10490924)/HTRA1 (rs11200638) variants are significantly associated with the risk of PCV in a Korean population. ARMS2/HTRA1 variants contribute significantly to the PCV phenotypes, including frequency of VH and mean BCVA at baseline.
Japanese Journal of Ophthalmology 09/2011; 56(1):60-7. · 0.92 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: To investigate whether there was an association with the LOC387715/HTRA1 variants and a response to combined photodynamic therapy with intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Combined photodynamic therapy with intravitreal bevacizumab was repeated every 3 months until the disappearance of angiographic signs in the active lesions of 51 eyes with polypoidal choroidal vasculopathy who were followed-up for at least 12 months. Patients were genotyped for LOC387715 and HTRA1 polymorphisms.
Although there was no significant difference in the baseline best-corrected visual acuity and fluorescein angiography-guided greatest linear dimension among the 3 genotypes in both genes, there was a significant difference at 12 months (P < 0.05, respectively). For LOC387715, the TT genotype showed greater fluorescein angiography-guided greatest linear dimension than the TG and GG genotypes (P = 0.035 and 0.006, respectively). The best-corrected visual acuity of the GG genotype was better than the TT and TG (P = 0.029 and 0.045, respectively). For HTRA1, the AA genotype showed greater fluorescein angiography-guided greatest linear dimension than AG and GG (P = 0.042 and 0.017, respectively). The best-corrected visual acuity of GG genotype was better than AA and AG (P = 0.018 and 0.040, respectively).
After combined photodynamic therapy with intravitreal bevacizumab treatment, LOC387715 TT and HTRA1 AA genotype had poorer outcomes at 12 months, suggesting a pharmacogenetic relationship.
Retina (Philadelphia, Pa.) 07/2011; 32(2):299-307. · 2.93 Impact Factor
-
The British journal of ophthalmology 12/2010; 94(12):1688-9. · 2.92 Impact Factor
-
Japanese Journal of Ophthalmology 05/2010; 54(3):246-8. · 0.92 Impact Factor
-
Japanese Journal of Ophthalmology 05/2010; 54(3):244-6. · 0.92 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: To classify polypoidal choroidal vasculopathy (PCV) presenting with both extramacular and macular lesions according to location and clinical manifestations.
We performed a retrospective analysis of 29 eyes presenting with both extramacular and macular PCV lesions by indocyanine green angiography. The patients were classified according to the location of the extramacular lesions and clinical manifestations.
PCV locations were identified as peripapillary (32.1%), superior (10.7%) or inferior (17.9%) to the optic disc, superior (14.3%) or inferior (7.1%) temporal arcade, temporal to the macula (10.7%), and nasal to the optic disc (7.1%). Clinical manifestations were identified as polyp (10.7%), branching vascular networks (42.9%), pigment epithelial detachment (PED) (17.9%), polyp and branching vascular networks (7.1%), polyp and PED (14.3%), and all three (7.1%).
PCV showed extramacular lesions with various clinical manifestations discontinuous from the macular lesions.
Japanese Journal of Ophthalmology 01/2010; 54(1):48-54. · 0.92 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: To study the clinical outcome and complications of intravitreal bevacizumab (IVB) versus triamcinolone acetonide (IVT) injections at the end of vitrectomy in patients with diabetic vitreous hemorrhage.
This is a retrospective comparative case study comprised of 156 eyes from 139 consecutive patients who underwent pars plana vitrectomy for diabetic vitreous hemorrhage (VH) with or without tractional retinal detachment (TRD). IVB (1.25 mg/0.05 ml) injection was done for 66 eyes (60 patients) and IVT (4 mg/0.1 ml) injection for 33 eyes (31 patients) at the end of vitrectomy, and no injection was done for 57 eyes (48 patients). Main outcome measures were best-corrected visual acuity (BCVA), intraocular pressure (IOP), and incidence of postoperative VH and reoperation with at least 12 months of follow-up.
Early postoperative VH within 1 month postoperatively occurred in eight eyes (12.1%) from the IVB group, three eyes (9.1%) from the IVT group, and 21 eyes (36.8%) from the control group. The rate of early postoperative VH was significantly lower in the IVB and IVT group than the control group (p = 0.002 and 0.006, respectively). Late postoperative VH after 1 month postoperatively occurred in 11 eyes (16.7%) from the IVB group, three eyes (9.1%) from the IVT group, and 12 eyes (21.1%) from the control group. There was no difference between the three groups (P = 0.341). BCVA of the IVB, IVT, and control group at postoperative months 1, 3, 6, 9, and 12 significantly improved from the preoperative BCVA (p < 0.01, respectively). There was no difference for BCVA between the three groups at each follow-up period (p > 0.05). In only the IVT group, IOP at postoperative day 1 was higher than IOP preoperatively (p = 0.002). There was no significant difference in the rate of reoperation between the three groups (p = 0.275).
IVB and IVT injection at the end of diabetic vitrectomy is a useful adjunctive therapy for reducing early postoperative VH compared to the control group. IVB injection does not have a risk of a temporary rise of IOP, which the IVT group has.
Albrecht von Graæes Archiv für Ophthalmologie 12/2009; 248(5):641-50. · 2.17 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Here, we report the case of a patient who sustained Nd: YAG laser macular injury with subsequent 6 year follow-up evaluation. A 23-year-old female was accidentally exposed to a Q-switched Nd: YAG laser without protective goggles. Upon initial evaluation, the best-corrected visual acuity of her affected eye was 20/100 OD. Fundoscopic examination revealed a macular laser burn and vitreous hemorrhage. Corticosteroids, in the form of 60 mg prednisolone, were administered orally with a 10 mg per week taper. Nineteen days following exposure, fundoscopic examination revealed a distinct epiretinal membrane which resolved within six months. The best-corrected visual acuity of the affected eye remained 20/100 OD. This clinical course is similar to those of previously reported cases including vitreous hemorrhage and subsequent epiretinal membrane formation. However, visual acuity did not recover despite spontaneous regression of the epiretinal membrane and at 6 year follow-up, there was neither choroidal neovascularization nor macular hole formation.
Korean Journal of Ophthalmology 09/2009; 23(3):207-9.
-
Japanese Journal of Ophthalmology 52(6):520-2. · 0.92 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The purpose of this study was to compare the clinical outcomes and complications between 23-gauge transconjunctival sutureless vitrectomy and 20-gauge vitrectomy in patients with proliferative diabetic retinopathy.
This is a retrospective comparative study comprising 101 eyes from 90 consecutive patients who had diabetic vitrectomy due to nonclearing vitreous hemorrhage. Thirty-five eyes underwent 23-gauge transconjunctival sutureless vitrectomy, and 66 eyes underwent 20-gauge vitrectomy. Main outcome measures were best-corrected visual acuity, intraocular pressure, and incidence of intraoperative and postoperative complications with at least 6 months of follow-up.
Best-corrected visual acuity of both groups at postoperative months 1, 3, and 6 significantly improved from the preoperative best-corrected visual acuity (P < 0.0001, respectively). There was no difference for best-corrected visual acuity between the 2 groups at each follow-up period (P > 0.05, respectively). Intraocular pressure of the 23-gauge group at postoperative Day 1 and Week 1 was less than the preoperative intraocular pressure (P < 0.0001 and 0.017). Operating time of the 23-gauge group was shorter than the 20-gauge group (P < 0.0001). There was no difference in the incidence of intraoperative and postoperative complications except transient postoperative hypotony, which occurred in 8 eyes (22.9%) from the 23-gauge group (P < 0.0001).
Twenty three-gauge transconjunctival sutureless vitrectomy appears to be as effective for proliferative diabetic retinopathy as 20-gauge vitrectomy.
Retina (Philadelphia, Pa.) 30(10):1662-70. · 2.93 Impact Factor
